Rolfe Lindsey's Form 4 filing
Clovis Oncology, Inc. (CLVS) · filed Mar 3, 2022
- Accession no.
- 0000899243-22-009062
- Filed
- Mar 3, 2022
- Trade date
- Mar 1-2, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $20.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rolfe LindseyCIK 0001650504 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2022 | Common Stock | MOption exerciseAcquired | +688 | –F1 | – | 87,177 | Direct | |
| Mar 2, 2022 | Common Stock | SSaleDisposed | −360 | $1.87F3 | −$673.2 | 86,817 | Direct | |
| Mar 1, 2022 | Common Stock | MOption exerciseAcquired | +20,250 | –F1 | – | 107,067 | Direct | |
| Mar 2, 2022 | Common Stock | SSaleDisposed | −10,585 | $1.87F3 | −$19,793.95 | 96,482 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2022 | Common Stock | AGrant or awardAcquired | +81,000 | $0.00 | $0 | 81,000 | Direct | |
| Mar 1, 2022 | Common Stock | MOption exerciseAcquired | +20,250 | $0.00 | $0 | 60,750 | Direct | |
| Mar 1, 2022 | Common Stock | MOption exerciseAcquired | +688 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each Restricted Stock Unit represents the right to receive one share of Common Stock.
Referenced by the price of 2 transactions in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $1.862 to $1.866. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 2 transactions in Table I.
Remarks
Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance